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Abstract
Timely progression of people living with HIV (PLHIV) from the point of infection
through the pathway from diagnosis to treatment is important in ensuring
effective care and treatment of HIV and preventing HIV-related deaths and
onwards transmission of infection.  Reliable, population-based estimates of
new infections are difficult to obtain for the generalised epidemics in
sub-Saharan Africa.  Mortality data indicate disease burden and, if
disaggregated along the continuum from diagnosis to treatment, can also
reflect the coverage and quality of different HIV services.  Neither routine
statistics nor observational clinical studies can estimate mortality prior to
linkage to care nor following disengagement from care.  For this,
population-based data are required.
The Network for Analysing Longitudinal Population-based HIV/AIDS data on
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The Network for Analysing Longitudinal Population-based HIV/AIDS data on
Africa brings together studies in Kenya, Malawi, South Africa, Tanzania,
Uganda, and Zimbabwe.  Eight studies have the necessary data to estimate
mortality by HIV status, and seven can estimate mortality at different stages of
the HIV care continuum.  This data note describes a harmonised dataset
containing anonymised individual-level information on survival by HIV status for
adults aged 15 and above. Among PLHIV, the dataset provides information on
survival during different periods: prior to diagnosis of infection; following
diagnosis but before linkage to care; in pre-antiretroviral treatment (ART) care;
in the first six months after ART initiation; among people continuously on ART
for 6+ months; and among people who have ever interrupted ART.
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Introduction
In 2014, an estimated 25. 8 million people in sub-Saharan Africa 
were living with HIV (PLHIV), representing 70% of the global total, 
and 790,000 HIV-related deaths occurred1. A third of these deaths 
occurred in six countries: Kenya, Malawi, Tanzania, South Africa, 
Uganda and Zimbabwe2. The network for Analysing Longitudinal 
Population-based data on HIV/AIDS in Africa (ALPHA)3 brings 
together health and demographic surveillance systems (HDSS) in 
these six sub-Saharan African countries, which have longitudinal 
data on participants and their HIV status.
These studies combine demographic, survey, clinical and verbal 
autopsy data to provide comprehensive, population-based estimates 
of the incidence of new HIV infections, the number of PLHIV, their 
experience of diagnosis and treatment, and their survival. For many 
PLHIV, these data permit estimation of seroconversion date and 
dating of diagnosis of infection, initiation of antiretroviral therapy 
(ART) and interruption of treatment.
Since the rollout of ART, overall adult mortality2,4–10, and that 
among PLHIV both on and off treatment, has fallen substantially11. 
However, the continuing high HIV mortality burden indicates 
that improvements in HIV testing, care and treatment are still 
needed.
For PLHIV, the continuum of care describes the steps necessary 
to achieve viral suppression2,12. Key transition points include 
diagnosis, assessment of ART eligibility, initiation of ART and 
viral suppression. Failure to progress in a timely manner from 
infection to diagnosis and from diagnosis to treatment will have a 
deleterious impact on mortality rates and onward HIV transmis-
sion.
Tracking PLHIV along each step of the HIV care continuum is 
challenging for several reasons2: Data on ART initiation and 
adherence are commonly available and readily collated from 
ART clinics with computerised records, but data on time of diag-
nosis and confirmation of eligibility for ART are less frequently 
recorded in formats that permit aggregation of those data for 
monitoring purposes. Furthermore, dates of seroconversion are not 
routinely estimated in the course of HIV testing or clinical care.
This data note describes a dataset containing harmonised survival 
data for DSS participants aged 15 years and above from eight 
studies in six countries over the period 1989–2014. The person-
time of PLHIV is categorised by stage on the HIV care continuum: 
a) had undiagnosed infection, b) had learned their HIV status, but
had yet to enrol in care, c) had received some pre-ART care, but had
not (yet) started treatment, d) were receiving ART continuously,
and e) had experienced an interruption in ART. Using these data, it
is possible to estimate mortality at different stages of the HIV care
continuum, and progression along the continuum.
Methods
Participating studies
Eight ALPHA Network studies could estimate mortality by HIV 
status over periods ranging from 4 to 26 years, and seven had 
data on HIV diagnosis and treatment: Karonga (Malawi)13; Kisesa 
(Tanzania)14; Kisumu (Kenya)15; Manicaland (Zimbabwe)16; 
Masaka (Uganda)17; Rakai (Uganda)18; uMkhanyakude (South 
Africa)19. Agincourt in South Africa20 had mortality data and 
partial HIV status data. The period with the most comparable data 
is 2005–14.
These studies are mainly ongoing rural HDSS21 and collect 
demographic data on the entire population resident in specific 
geographical areas via frequent, focussed enquiries, and conduct 
regular home- or community-based HIV testing of the resident 
adult population. Additional socio-economic, HIV-related and 
sexual behaviour data are collected via questionnaire-based 
surveys. In uMkhanyakude there were no self-reported data on 
uptake of HIV care and treatment.
All resident adults are eligible for HIV testing, with the excep-
tion of Kisumu and Manicaland where HIV testing is restricted 
to a smaller, representative, cohort within the study. For the 
period in question, only Karonga and Kisumu returned HIV 
results automatically to participants, but all participants had the 
opportunity to find out their status by opting to receive the results 
of the research test or by undergoing HIV testing and counselling 
(HTC) in parallel with the research testing and in accordance with 
contemporary local standards for HTC, described elsewhere3.
The ALPHA network partners are independent research institu-
tions, and began fieldwork at different times and with differing 
research priorities. Consequently, there is variation in study pro-
tocols and the data available. Recently, these studies have begun 
to link their population-based data with clinical data from local 
health facilities, but the information available from health facility 
records and the methods used to link these data to the HDSS 
vary. Four studies (Kisesa, Masaka, Rakai and uMkhanyakude) 
linked visit-level data from local ART clinics to the HDSS data. 
Administrative changes in clinics interrupted data linkage with 
the HDSS after 2012 in Rakai and 2013 in uMkhanyakude. Two 
studies (Karonga and Kisumu) had summary information from 
ART clinics linked to HDSS records. No clinical data were 
available for Manicaland, but some information on treatment was 
available from self-reported survey data. Detailed information is 
given in Box 1.
It is worth noting that the period covered by these data includes 
the early phase of ART provision in these communities, and the 
decentralisation of treatment. Provision of treatment went ahead 
of strengthening clinic systems for monitoring and reporting on 
ART initiation, adherence and other relevant clinical measures. 
Many of the clinics that provide treatment to HDSS participants 
do not have electronic medical records (EMR) not least due to a 
lack of reliable electricity. During this period, most clinics could 
not easily undertake CD4 counts, and there was no viral load testing 
or resistance screening. Thus the standard of care for a typical clinic 
visit may compare unfavourably to that of high-income settings at 
the time. In addition, the lack of EMR means that some observa-
tions were not systematically recorded, for example, in many cases 
consultations were summarised in freehand notes. Such informa-
tion is cumbersome and expensive to extract from handwritten 
logbooks and registers, and has thus not been included.
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Box 1. Details of clinic data available from each site and the 
methods used to link these data with the population-based 
data.
Karonga 
Links between the health and demographic surveillance system 
(HDSS) and clinical records were made by study fieldworkers in 
all 16 clinics that provide ART in the area. Those attending were 
interviewed and identified in the HDSS database. Initially, links were 
made only in ART clinics, so there is little information on pre-ART 
care. Clinical records were summarised every 6 months, and data 
to 2016 were shared with ALPHA. 
Kisesa 
Links between the HDSS and clinical records were made in two 
ways. Probabilistic links based on names, date of birth and place 
of residence were made for records from two HIV clinics from mid-
2015 onwards. Individuals identified as HIV positive in the sero-
survey or at routine HIV testing and counselling (HTC) in the HDSS 
study area were referred to local care providers, and their referral 
was tracked to enable ongoing linkage between clinical records 
and the HDSS. 
Kisumu 
A summary of patients’ records was made annually since 2009 from 
the 19 clinics providing HIV care. Probabilistic and deterministic 
links were made using the Kenyan national identity number and 
other identifying information. 
Masaka 
Since 2012, all HIV positive participants have been routinely 
referred to the clinic run by the study which uses the same identifier 
as the research project. Pre-2012, those in selected clinic studies 
and those attending HTC were referred to the clinic and linked. 
Rakai 
Between 2004 and 2013, Rakai had good coverage of 19 HIV care 
clinics in the area covered by the HDSS and used probabilistic 
methods to link data with the HDSS. However, in 2013 the system 
for sharing clinic data with the HDSS changed and data are not 
available from that point onwards. 
uMkhanyakude 
Deterministic links between the HDSS and 21 HIV care and 
treatment clinics serving the HDSS area were made using South 
African national identity numbers and referrals tracking from the 
HDSS. Probabilistic record linkage was done whenever national ID 
numbers were not available.
The information needed to identify time spent in pre-ART care 
(still an important stage on the continuum during the period cov-
ered by these data) was not available for PLHIV in Manicaland (via 
self-report) or for most PLHIV in Karonga. Additionally, nobody 
in Manicaland is classed as having interrupted ART because the 
survey question on interruption of treatment did not permit dating 
of this event.
Local researchers supplied the dates at which ART first became 
available in at least one government health facility in each HDSS 
area, and the date when the ART rollout to all local health facilities 
designated as ART providers under national ART policy guidelines 
was complete.
Transitions and stages on the continuum of care for HIV
The primary purpose for constructing this dataset was to describe 
and compare mortality at different stages of the care continuum 
over time and between studies. Given the data available across the 
different studies, we defined stages of the HIV care continuum 
based on: The estimated date of seroconversion from HIV 
negative to positive and the date of diagnosis of HIV infection, 
enrolment in HIV care, initiation of ART, stabilisation on ART and 
first interruption of ART. High quality data to describe temporary 
or permanent disengagement from pre-ART care or date of first 
ART eligibility were not available. The stages of the HIV care 
continuum are the intervals between these transitions. The care 
continuum, as described above, is a one-way system since people 
cannot return to a category after leaving it. Those who had a gap 
in treatment of longer than one month and those who had 
discontinued ART, at any time after initiation, were allocated to a 
group of people who had experienced an interruption in treatment, 
which included those who subsequently resumed ART.
Viral load was not routinely measured in the clinics serving these 
populations and so we could not identify people who achieved viral 
suppression. In lieu, we used a period of time on ART (more than 
six months without interruption), and used that classification as a 
proxy for stabilisation on treatment.
Data sources and availability
Data from each study were harmonised to standard specifications 
for analysis (Table 1, also see http://alpha.lshtm.ac.uk/metadata/ for 
the detailed specifications) although not all datasets were available 
from every study.
Analytical methods for preparation of the dataset
Data from all HDSS participants, regardless of HIV status, were 
prepared for survival analysis based on residency data using Stata 
1522. Entry into the study was on the 15th birthday or the date of first 
in-migration to the HDSS area (if already aged over 15), or the date 
of enumeration in the baseline study round. Exit was the date of 
out-migration or death. Gaps in residency due to temporary migra-
tion were recorded as such in the analysis. Surviving residents were 
censored at the time of their last HDSS observation. The dataset is 
organised to have multiple records for each individual, with each 
record corresponding to a short period of exposure which permits 
estimation of mortality by age, calendar time and HIV, diagnosis 
and treatment status. In Stata22 terminology, this means the data 
have been stset and stsplit (see page 377 of the Survival Analysis 
Reference Manual23).
Assignment of HIV status
Person-time was allocated to one of three HIV status categories 
(unknown, negative, positive). Individuals could move through 
all three categories during study follow-up. HIV status informa-
tion was available from a) periodic research HIV tests, b) linked 
clinic data, and c) self-report. Prior to first HIV test, individual 
HIV status was classed as unknown. The time between two nega-
tive tests was classed as negative and for the purpose of calculat-
ing mortality among HIV-negative adults, the period after the last 
HIV negative test was classed as negative for a short period, after 
which person-time was classed as unknown. For each study, the 
period of time classed as negative after the last negative test was 
based on the observed local incidence rates and the cut-off point 
was defined as the time by which 5% of people of the same age and 
sex had seroconverted. This ranged from 2 to 50 years in the East 
Page 4 of 16
Gates Open Research 2017, 1:4 Last updated: 07 DEC 2017
Table 1. ALPHA standard datasets available from each site.
ALPHA standard datasets:
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1 Information on residence in the study area, 
including dates of birth, migration and death. ● ● ● ● ● ● ●
2 History of HIV testing, including dates of tests, 
circumstance in which test was carried out, final 
test result, and whether or not the test result was 
returned to the participant.
● ● ● ● ● ● ●
3 Verbal autopsy data. ● ● ● ● ● ● ●
4 Self-reported information, from periodic surveys, on 
use of HIV testing services, disclosure of HIV status, 
use of HIV care and treatment services, ART use 
and interruption of ART.
● ● ● ● ● ●
5 HIV clinic records on enrolment in care and ART 
history. ● ● ● ● ● ●
African studies (mean 10·8) and from 1 to 50 years in the South-
ern African studies (mean 2·8). Individuals were assigned as HIV 
positive immediately after the first positive research test. People of 
hitherto unknown HIV status who were identified in HIV or ART 
clinics were classified as positive from the date of the first visit to 
the clinic. In Kisumu, participants could report their HIV status in 
lieu of a test and those results were used for people without a test 
result (less than 3% of participants).
People who were observed to seroconvert were treated exactly the 
same way as all other people who had tested negative and were 
categorised as positive only after the first positive test. Those for 
whom the interval between the last negative and first positive tests 
exceeded the cut-off were classified as unknown for a period prior 
to the first positive test.
Assignment of person time and deaths to stages on the 
HIV care continuum
Information on HIV diagnosis status, use of HIV-related care and 
ART history came from:
a)    receipt of HIV test result following periodic HDSS research 
tests
b)    self-report of HIV test history, diagnosis, pre-ART care and 
ART use, including dates
c)    linked clinic data, primarily on pre-ART care and ART
The information used from each source is detailed in Table 2. A 
greater amount of information on experience of HTC, and thus 
diagnosis date, was available from self-reported and study data 
than from clinic data, whereas ART histories were derived almost 
entirely from clinic data.
Some individuals had information on a transition from more than 
one source, but no source of data is clearly superior. Clinic data 
did not contain information on diagnosis and did not include peo-
ple who used clinics outside the study area. Self-reported data may 
quickly become outdated, but can include interactions with a wide 
range of service providers if PLHIV are willing to disclose their 
status to the interviewer. We considered using algorithms to give 
more weight to data from either clinic data or self-reported data for 
the transitions that could be identified in both data sources, but con-
cluded that it was not possible to systematically deem one source 
to be more reliable than the other in all circumstances. Therefore, 
we took the earliest reported instance of any of the transitions as 
the date for that change regardless of the source of that data. We 
discarded self-reported dates that were implausible (such as, ART 
initiation before birth), but imposed no other constraints. Thus if, 
for example, a self-reported start date for ART was before the first 
positive test in the study, we backdated the HIV positive person 
time to the reported date of ART initiation.
Some participants retrospectively reported the dates when they 
made a transition (first positive diagnosis, linked to care, started 
ART, interrupted ART). For this analysis of mortality we did not 
use the retrospectively reported date but instead used the date of 
first report. This was to avoid biasing the data towards survivors, 
who were able to make a retrospective report of their progression 
along the continuum which those who had died before the survey 
could not do.
HIV positive person-time was allocated to one of the continuum 
stages listed in Table 2 based on a synthesis of all the informa-
tion available for each person and each transition. If at least one 
source indicated that an individual had made a transition, then 
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Table 2. Categories on the HIV care and treatment continuum.
Person years 
assigned as:
Description Information used
Study research 
tests
Self-report Clinic data
Undiagnosed Never been told has 
HIV
Never given 
test results by 
study since first 
testing positive
Never received a test result* 
Not received a test result since first 
recorded positive test
Not used, cannot confirm 
undiagnosed status
Diagnosed Has received >=1 
positive test result
Has been given 
a positive test 
result by study
Reports having received a test result 
after date of first recorded positive 
test
Not used
In care Has attended (>=1 
occasion) an HIV 
service or care clinic 
but has never had ART
- Reports having attended HIV care 
services at least once. No restriction 
on type of service or frequency of 
visit. (ART naïve)
Attended an HIV care clinic on 
at least one occasion  
(ART naïve)
Early ART Started ART within 
the past 6 months, no 
breaks
- First 6 months after reported start 
date for ART and no gaps reported/
before first gap
First six months of continuous 
attendance at ART clinic
Stable ART Been on ART longer 
than 6 months without 
a break
- More than 6 months after reported 
start date for ART and no gaps 
reported (includes time before first 
gap)
After six months of continuous 
attendance at ART clinic or, if 
initiation not captured, 
continuous attendance since 
first visit in someone who 
initiated ART elsewhere or 
before the clinic’s data were 
linked with the HDSS
Interrupted ART Started ART but has 
experienced one or 
more gaps of 1 month 
or more in treatment
- After first reported interruption in 
ART
Unknown Insufficient information 
to allocate to any of the 
above groups
-
* Distinction between taking an HIV test and receiving the results is not possible in some rounds in Masaka.
their person-time following that transition was allocated to the 
subsequent stage on the continuum. This process was repeated if 
information was available on subsequent transitions. After the last 
observed transition, all the remaining person-time was allocated 
to the last recorded stage. Transitions that occurred when the indi-
vidual was not under observation in the study (due to temporary out 
migration) were recorded as occurring at the time that the individual 
returned to observation to avoid biasing the data towards temporary, 
rather than permanent, outmigrants and to survivors.
In addition to information on the dates when individuals made 
the various transitions, we also had dates at which a particular 
transition had not already been made from null reports in self-
reported survey data (i.e. does not know HIV status, has never 
been to HIV care, has never taken ART, has never stopped taking 
ART) and from clinic history (has never started ART, has never 
stopped taking ART). Therefore person-time allocated to each 
individual’s final stage can be disaggregated into time when the 
individual is known not to have made the transition to the next 
stage and the person-time contributed by people for whom there is 
no evidence regarding the next transition. For mortality analyses, 
we did not separate the person-time in the final stage into these 
two groups, or use this information to censor the follow-up time, 
because there is a zero probability of mortality in the time before 
the final null report.
Continuity of care and adherence to ART
We identified anyone who ever self-reported or had been observed 
to have a break in treatment and distinguished these individuals 
from those who never interrupted ART. We were not able to make 
this same distinction for pre-ART care due to a lack of data for 
PLHIV in this stage. Based on clinic data, continuous attendance 
was defined as PLHIV attending appointments not more 
than one month after: a) next recorded scheduled visit, b) time 
when their pills ran out (based on records of pills dispensed at 
previous visit), or c) the interval between visits specified in national 
guidelines. This interval ranged from 1 to 3 months. PLHIV 
for whom we had only self-reported data regarding ART were 
assumed to be continuously on ART until they reported stopping 
or interrupting ART. When this was reported, or when a gap was 
identified in clinic data, PLHIV were moved to the last stage: 
interrupted ART.
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Relative size and annual coverage of the different studies
For each study site, the total number of individuals included in this 
dataset is determined by the size of the population participating 
in demographic surveillance and the length of time the study has 
been in existence. The number of PLHIV included is further deter-
mined by the HIV prevalence and participation in survey rounds 
that included HIV testing. The proportion of participants who were 
HIV positive at the most recent survey ranged from 6% in Karonga 
to 33% in uMkhanyakude.
The average number of PLHIV under observation in each HDSS, 
for the periods i) before the introduction of ART; ii) during 
ART roll-out; and iii) once ART was widely available, are shown 
in Figure 1.
In terms of the number of individuals followed, the largest is 
uMkhanyakude in South Africa (approximately 63,000 adults in 
early 2012), followed by Kisumu in Kenya (circa 47,000 adults 
in early 2012), which began population-wide HIV testing in 
Figure 1. HIV positive person time by site and calendar year. Numbers in brackets give total number of PLHIV ever identified.
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2005 and 2008, respectively. We used only part of the Kisumu data, 
that from Gem district, which has more HIV data than the other 
two districts. The studies with the longest follow up are Masaka 
(beginning 1989) in Uganda and Kisesa in Tanzania (beginning 
1994), which had, respectively, approximately 10,000 and 16,000 
adults under observation at the start of 2012.
The introduction of ART occurred at different times in the dif-
ferent sites and the interval between introduction and widespread 
availability varied markedly ranging from one year in Masaka 
to 3·5 years in Kisesa and Manicaland in Zimbabwe.
Description of variables
The variables and coding, where relevant, are given in Supplementary 
File 1.
Dataset validation
Availability of linked clinic data
The ability to link clinical records to HDSS data varies between sites 
and has changed over time. Table 3 shows, by study, the number 
of PLHIV observed during 2005, 2010 and 2014 and the percent-
age for whom clinic data were available. The proportion of peo-
ple with linked clinic data available represents the extent to which 
PLHIV are diagnosed and enrolled in care, and also the ability 
of the study site to link DSS and clinical records. In Kisesa, the 
total number of PLHIV fluctuates markedly because new HIV 
positives are identified once every 2–3 years, but exits due to death 
and out-migration are recorded approximately every 6 months in 
the HDSS.
Data availability over time, by HDSS and transition along 
the continuum
There were important differences between the studies in the 
availability of data. The time covered by each data source is 
shown in Figure 2 and is disaggregated for each transition. The 
absolute numbers of transitions observed within each study varies 
substantially and so, to facilitate cross-study comparison, the height 
of each coloured band indicates, within a study, the relative 
number of transitions in each year, for each source, expressed as a 
proportion of the largest group in the study (at any time point).
Impact of intermittent reporting on data quality
The validity of our results is determined by the timeliness of 
our data, and the degree to which we base our classification of 
person-years on outdated information. ALPHA studies collect 
survey data every one to three years, depending on study site, 
and the time elapsed between individual reports may be longer 
because a) individuals do not always participate in every round, and 
b) questions may have been omitted from some rounds.
Person-time after an observed transition is, by default, allocated to 
the next stage on the continuum. For example, after a positive test 
where there is no record of results being reported to the individual, 
person-time is allocated to the undiagnosed stage until the date of 
diagnosis/linkage to care or ART, if this occurs and is recorded. We 
may have one (or more) reports that the person has not yet learned 
their HIV status and that allows us greater certainty about the allo-
cation of time to the undiagnosed stage. Following such a report, 
the chance of misclassification (the person learning their status but 
we fail to capture that information) increases with time since the 
last report.
Examining the distribution of these null reports (a report stating 
that a transition has not been made) allows us to see how cer-
tain we are regarding allocation of person time to each category. 
Figure 3 shows the distribution of person-time amongst PLHIV 
that was allocated to stages on the HIV care continuum based on 
not having made certain transitions: not diagnosed, not linked to 
care and not on ART (ART naïve). The total person-time in these 
states is summed and the figure shows the proportions of that time 
that were a) before a null report regarding the subsequent transi-
tion, b) less than two years after the last null report regarding the 
subsequent transition, and c) more than two years after the last null 
report. The fourth category shows person-time contributed by indi-
viduals for whom we have never had any information regarding the 
subsequent transition.
Pre-diagnosis has the greatest share of person-time prior to the 
last report, the lowest proportion where there is no evidence either 
way, and a high proportion of person time within two years of the 
last report on diagnosis status. This is because in most studies this 
Table 3. Number of people living with HIV (PLHIV) and the percentage linked to 
clinical records by study and year.
Study 2005 2010 2014
Number 
PLHIV
% linked to 
clinic
Number 
PLHIV
% linked 
to clinic
Number 
PLHIV
% linked 
to clinic
Karonga 124 67.7 1296 54.6 1339 70.1
Kisesa 395 2.5 584 13.9 570 8.4
Manicaland 2571 0.0 2222 0.0
Masaka 622 54.5 772 60.1 769 61.0
Rakai 1149 33.6 1609 47.9 1135 44.7
uMkhanyakude 4034 5.5 9705 46.5 11584 48.4
Kisumu 183 100.0 1938 65.3
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Figure 2. Data available from each study by data source and continuum stage, over time.
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Figure 3. HIV positive person years prior to each transition along 
the continuum by the existence and recency of the information 
used to place them.
information is collected systematically at the same time as the HIV 
testing is conducted for research purposes and, in all studies except 
uMkhanyakude, participants are asked about testing history.
The transition to pre-ART care is the most poorly described, in part 
because pre-ART care was not as widely or systematically avail-
able as treatment. Five studies had no null information because 
this transition is only recorded by the arrival of the individual in an 
HIV care clinic. In Kisesa and Rakai this information is collected 
in self-report, which is why there is some person time known to be 
pre-transition.
The transition to ART is well described, with the exception of 
Kisesa, but despite that in most studies a substantial minority of 
person-years are classified as ART-naive by default because there 
is no evidence either way. Note that many of those individuals do 
have information on diagnosis.
Ethical policies
Best practice regarding HIV testing for research purposes has 
changed during the lifetime of these studies. The earliest data 
collection made use of informed consent without disclosure. After 
treatment became available, research testing was accompanied by 
opportunities for participants to learn their status using a variety of 
locally approved protocols.
Local ethical approval for these analyses was obtained by each 
study. The harmonisation and analysis of the pooled mortality data 
was approved by the ethics committee of the London School of 
Hygiene and Tropical Medicine (ref 6467) on 23rd August 2013.
Consent
Written informed consent for analysis of the participants’ 
anonymised details and publication of the results was obtained 
from the participants or, for verbal autopsy data, from a relative 
of the deceased participant.
Data availability
The ALPHA Network harmonises the data produced by a diverse 
group of longitudinal HIV studies. Ownership of the data rests 
with the studies, or in some cases with the national government. 
The member studies have shared their data with the Network, but 
have not transferred ownership. The dataset is maintained by Emma 
Slaymaker, but access to the data is conditional on obtaining per-
mission to use each study’s data. Requests for permission to use the 
data should be directed to the ALPHA Network contact person in 
each study:
Study Contact Point of contact
Karonga Amelia (Mia) 
Crampin
http://meiru.lshtm.ac.uk/
Kisesa Mark Urassa via ALPHA
Kisumu Daniel Kwaro dkwaro@kemricdc.org
Manicaland Simon Gregson http://www.
manicalandhivproject.
org/data-access.html
Masaka via ALPHA
Rakai Tom Lutalo tlutalo@rhsp.org
uMkhayakude via the Africa 
Health Research 
Institute data 
repository
help@africacentre.ac.za
The ALPHA Network can facilitate such enquiries (http:// 
alpha.lshtm.ac.uk/). Requests should state the name of the 
dataset: ALPHA_Gates_ready_2015_pooled_2_Aug_2017.dta.
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Supplementary File 1: Description of variables.
Click here to access the data dictionary.
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 Tracy R. Glass
Department of Clinical Research Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland
This paper describes the valiant efforts of many people to collect quality data for research purposes. From
experience in just one of these countrie’s HDSS data collection, I know the challenges they have faced.  I
think they did a good job attempting to give an accurate picture of the data they collected and its
limitations both for use and for drawing valid and generalizable conclusions.
Is the rationale for creating the dataset(s) clearly described?
Yes
Are the protocols appropriate and is the work technically sound?
Yes
Are sufficient details of methods and materials provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 04 December 2017Referee Report
doi:10.21956/gatesopenres.13813.r26075
 Matthias Egger
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
This is the first time I review a Data Note for Gates Open research. According to the instructions for
authors, “Data Notes are brief descriptions of research datasets that include details of why and how the
data were created; they do not include any analyses or conclusions”. In general I felt the data note on the
network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) is well written and
I have approved it. The report could be a bit more detailed and clear in some places, and I have made
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1.  
2.  
3.  
4.  
5.  
6.  
7.  
8.  
9.  
10.  
11.  
I have approved it. The report could be a bit more detailed and clear in some places, and I have made
suggestions for improvements below. These can all be dealt with within a minor revision.
 
The longitudinal studies participating in ALPHA were set up for different reasons and with different
research priorities. It would be helpful to detail these reasons and priorities in greater detail. What
were the primary research objectives of the different studies? What is the primary research
objectives of ALPHA?
 
Clearly, the studies were not established to study the HIV cascade of care and data were obtained
from different sources, including documented test results from HDSS surveys, linked clinic data,
and self-reported data. I was surprised to read that “it was not possible to systematically deem one
source to be more reliable than the other …”. Isn’t a documented HIV test more reliable than a
self-reported HIV status? Could this be clarified?
 
Following from above, if data from different sources were available, could the validity of the
different sources be assessed, for example by considering documented test results as the gold
standard. This might allow corrections, for example for social desirability bias. Please comment.
 
It would be useful to know how many participants had a negative HIV test before their positive test?
Also, how many individuals were considered HIV positive because they attended HIV clinics,
without any testing data? Can this be gleaned from Figure 2? Not entirely clear to me.
 
A time window of 1 month seems rather short to define interruption of treatment, and prone to
misclassification due to data errors. Any single undocumented visit or pharmacy claim is likely to
lead to misclassification of patients as interrupted treatment. Please comment on the choice of this
window – usually longer windows are chosen (3 months or 6 months).
 
How exactly were the HDSSs and clinic data linked? I would have thought a data note would
exactly be the place where some technical details should be provided on the type of probabilistic or
deterministic linkage used.
 
The section on the Assignment of HIV status is not entirely clear. First the authors say that the
period after the last HIV negative test was classed as negative for a short period (how short?) but
then go on to state that the period of time classed as negative after the last negative test was
based on the observed local incidence rates, that the cut-off point was defined as the time by
which 5% of people had seroconverted (how was this threshold chosen?) and that this ranged from
2 to 50 years in the East African studies. Please clarify.
 
It would be interesting to see a discussion of how a cascade of care can be constructed using
these data, including the definition of numerators and denominators at each step of the cascade,
and what particular issues arise in the different studies.
 
Important limitations of the dataset include the lack of CD4 cell and viral load data, and the time
period covered, which for some studies ends in 2012. This could be discussed in greater detail,
particularly in the light of the recent changes in WHO guidelines (“treat all”).
 
Figure 2 needs more explanation and a scale for the horizontal bars that vary in width over time.
 
No datasets are provided and I could therefore not assess the question: “Are the datasets clearly
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11.  No datasets are provided and I could therefore not assess the question: “Are the datasets clearly
presented in a useable and accessible format?”
Is the rationale for creating the dataset(s) clearly described?
Partly
Are the protocols appropriate and is the work technically sound?
Yes
Are sufficient details of methods and materials provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
No
 I collaborate with some of the authors within the framework of the InternationalCompeting Interests:
epidemiological Databases to Evaluate AIDS (IeDEA) and the Measurement & Surveillance of HIV
Epidemics (MESH).
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 01 December 2017Referee Report
doi:10.21956/gatesopenres.13813.r26079
 Mary-Ann Davies
Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South
Africa
This is a well written article describing the data available in the ALPHA network that could potentially be
used to assess mortality along the HIV care continuum.
My specific comments are outlined below.
Abstract: Among PLHIV, the dataset provides information on survival during different periods: prior to
diagnosis of infection; following diagnosis but before linkage to care; in pre-antiretroviral treatment (ART)
care; in the first six months after ART initiation; among people continuously on ART for 6+ months; and
among people who have ever interrupted ART.
Given the sentence above – as well as the title of the article, I was expecting that the article would actually
describe the survival (or its inverse – the mortality) during the different steps along the care continuum.
However the article’s focus is actually on the data that is available to describe this mortality, rather than on
survival or mortality itself. I suggest that the title and abstract are reworded to make this clear that the
article is about the availability and quality of data from the alpha network that could be used to examine
mortality along the HIV care continuum, rather than suggesting that the article will describe mortality itself.
Perhaps the title should read: “The Network for Analysing Longitudinal Population-based HIV/AIDS data
on Africa (ALPHA): Assessing the availability and quality of data on mortality…”
 
Methods: Some participants retrospectively reported the dates when they made a transition (first positive
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Methods: Some participants retrospectively reported the dates when they made a transition (first positive
diagnosis, linked to care, started ART, interrupted ART). For this analysis of mortality we did not use the
retrospectively reported date but instead used the date of first report. This was to avoid biasing the data
towards survivors, who were able to make a retrospective report of their progression along the continuum
which those who had died before the survey could not do.
This is not completely clear. I fully understand the need to make some adjustment to avoid biasing the
data towards survivors, but it is not clear to me how using the data of first report rather than the
retrospectively reported date would achieve this. Surely this would mean that for many patients who
retrospectively report they have been diagnosed, linked to care and started ART and interrupted ART it
would appear that all of these events happened on the same day. Since this is an article about data
validation it may also be helpful to actually show what the difference would be using the date of first report
vs the retrospectively reported date.
 
Dataset validation: Availability of linked clinical data.
The proportion of people with linked clinic data available represents the extent to which PLHIV are
diagnosed and enrolled in care, and also the ability of the study site to link DSS and clinical records.
Since proportion of people linked to clinic is a combined outcome both of actually linking to care (a key
clinical and programmatic outcome that we really want to measure accurately) and ability of the study site
to link DSS and clinical records –which is a research function and has nothing to do with program
performance or clinical outcomes, it seems odd to present this is a combined outcome which is really not
meaningful, particularly when the percent linked to clinic ranges from 0-100%. I am not sure of the value
of this table or of presenting the information unless it is possible to separate the two outcomes or to
validate in some way for each site among the diagnosed people actually linked, what proportion the study
is able to identify as linked.
I found Figure 2 very difficult to interpret and am not sure what the key message is. I suggest this is made
clearer. I think a table with absolute numbers may be clearer as well as some summary text highlighting
the key messages.
The article doesn’t seem to have a “Conclusion” or “Take home message”. This would be very helpful and
I would suggest that the authors add this.
Is the rationale for creating the dataset(s) clearly described?
Yes
Are the protocols appropriate and is the work technically sound?
Yes
Are sufficient details of methods and materials provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
No
 No competing interests were disclosed.Competing Interests:
Referee Expertise: HIV cohort research, pediatric HIV clinical epidemiology
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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